Estriol 0.01% | Hydrocortisone 0.5% | Hydroquinone 6% | Kojic Acid 6% | Tretinoin 0.05%

Route: Topical application to facial or affected skin.

Apply a thin, even layer to cleansed, dry affected areas. Patients should avoid eye, nasal, and oral mucous membrane contact. Due to the presence of tretinoin, this preparation is typically applied at nighttime. A broad-spectrum sunscreen (SPF ≥30) must be applied every morning during treatment, as tretinoin and hydroquinone increase photosensitivity. Patients should use sunscreen and protective clothing consistently throughout the course of therapy. Avoid use on broken, inflamed, or sunburned skin.

Dosing regimen and application frequency are determined by the prescribing clinician. Typical clinical practice for multi-agent depigmenting creams:

• Apply a thin layer to hyperpigmented areas once daily (typically at night) or as directed.
• A limited application area (affected spots only vs. full face) should be specified by the prescriber.
• Treat in defined cycles (e.g., 8–12 weeks), followed by reassessment, as prolonged continuous use of high-strength hydroquinone is generally limited to 4–6 months per course to avoid ochronosis.
• The prescriber should individualize duration, cycle length, and frequency based on skin type, pigmentation severity, and tolerability.

• Estriol (0.01%): Binds cutaneous ERα and ERβ to upregulate collagen I/III synthesis, promote skin hydration, and potentially modulate melanocyte-stimulating hormone receptor signaling in the epidermis.
• Hydrocortisone (0.5%): Binds glucocorticoid receptors in keratinocytes and dermal fibroblasts; suppresses NF-κB and AP-1 signaling to reduce pro-inflammatory cytokine production (IL-1β, TNF-α) and prostaglandin synthesis, diminishing inflammation-driven melanocyte stimulation.
• Hydroquinone (6%): Competitively inhibits tyrosinase (the copper-containing enzyme catalyzing conversion of tyrosine → DOPA → dopaquinone); also inhibits melanocyte DNA and RNA synthesis and may disrupt melanosome structure and transfer to keratinocytes.
• Kojic Acid (6%): Chelates copper at the tyrosinase active site, inhibiting both monophenolase (tyrosine → DOPA) and diphenolase (DOPA → dopaquinone) activities; acts additively or synergistically with hydroquinone for broader tyrosinase inhibition.
• Tretinoin (0.05%): Binds RAR-α/β/γ nuclear receptors, which form RXR heterodimers and bind retinoic acid response elements; increases keratinocyte proliferation and corneocyte shedding, disperses melanin granules, reduces tyrosinase activity, and stimulates procollagen synthesis, improving both pigmentation and photoaged skin architecture.

Clinical Context: This five-ingredient topical formulation is designed for prescriber-directed management of facial hyperpigmentation conditions including melasma, post-inflammatory hyperpigmentation, and solar lentigines. The combination of tyrosinase inhibitors (hydroquinone, kojic acid), a retinoid (tretinoin), a low-potency corticosteroid (hydrocortisone), and local estrogenic support (estriol) targets multiple steps in melanogenesis simultaneously.

Monitoring Considerations:

• Reassess clinical response, skin tolerability, and signs of cutaneous irritation at 4–8 week intervals.
• Limit continuous hydroquinone use to 4–6 months per treatment cycle; exogenous ochronosis (paradoxical blue-black hyperpigmentation) is a rare but documented risk with prolonged high-concentration use.
• Tretinoin may cause retinoid dermatitis (erythema, peeling, dryness) during initiation; counsel patients accordingly and adjust application frequency if needed.
• Monitor for skin atrophy or secondary infection with topical corticosteroid use, particularly if application area is large or occlusive dressing is used.
• Avoid during pregnancy: tretinoin is teratogenic (Category X/FDA Warning); high-dose hydroquinone during pregnancy is also not recommended.

Contraindications:

• Pregnancy (tretinoin is teratogenic; avoid this combination in women who are or may become pregnant).
• Breastfeeding (safety of topical tretinoin and high-strength hydroquinone during lactation is not established).
• Hypersensitivity to any of the five active ingredients or excipients.
• Application to actively inflamed, infected, broken, or sunburned skin.

Warnings & Precautions:

• Strict photoprotection (SPF ≥30 broad-spectrum) is mandatory throughout treatment; failure to protect from UV exposure significantly reduces efficacy and worsens hyperpigmentation.
• Hydroquinone at 6% is above OTC limits (max 2% OTC); this is a prescription-grade concentration. Exogenous ochronosis risk increases with prolonged use; limit continuous courses.
• Retinoid dermatitis: initial erythema, scaling, and photosensitivity are expected with tretinoin; reduce application frequency if severe.
• Avoid contact with eyes, lips, and mucosal surfaces.

Drug Interactions:

• Other topical retinoids or exfoliants (AHAs, BHAs): additive irritation; avoid concurrent use on the same area.
• Topical benzoyl peroxide may oxidize and inactivate tretinoin; do not apply in the same session.
• Broad-spectrum systemic retinoids: additive systemic retinoid toxicity risk; contraindicated.

Common Side Effects: Erythema, dryness, peeling, and stinging/burning (primarily tretinoin-related); skin lightening beyond intended areas (hydroquinone/kojic acid); transient darkening before lightening; cutaneous irritation. With prolonged corticosteroid use: skin thinning and secondary infection risk.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from heat and light; tretinoin degrades with UV exposure. Keep tightly capped. Do not freeze. Keep out of reach of children. Use before the beyond-use date (BUD) on the label as assigned by Genesis Compounding.

Why are there five active ingredients in this cream?

Hyperpigmentation involves multiple pathways: melanin production, its transfer to skin cells, inflammatory triggers, and skin cell turnover. Each ingredient in this formula targets a different step simultaneously — making combination therapy more effective than any single agent alone.

Why must I wear sunscreen every day?

Tretinoin and hydroquinone both increase the skin's sensitivity to UV radiation. Sun exposure can not only cause irritation but can actively worsen hyperpigmentation and negate the benefits of treatment. Daily broad-spectrum SPF ≥30 is essential throughout the course of therapy.

Is this cream safe in pregnancy?

No. Tretinoin is contraindicated in pregnancy due to teratogenicity. Women who are pregnant, planning to become pregnant, or breastfeeding should not use this preparation. Discuss safe alternatives with your prescriber.

How long will it take to see results?

Visible lightening of hyperpigmentation typically begins within 4–8 weeks, with more significant improvement at 8–12 weeks. Full results require consistent use with strict sun protection.

Is this product FDA-approved?

No. This is a 503A compounded preparation made by Genesis Compounding specifically for your prescription. The individual active ingredients have established pharmacological profiles, but this multi-ingredient combination has not been reviewed by the FDA as a finished drug product.